microRNA在皮肤黑色素瘤血清与毛发中的差异表达

Abstract
Figure/Table
References (20)
Related Citation (14)

Download: PDF (625 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the differential expression of microRNAs in cutaneous malignance melanoma in order to provide a basis for the diagnosis and targeted treatment of this malignancy; to screen seven specific microRNAs in serum and hairs of cutaneous malignancy melanoma. Methods From March 2016 to October 2017, 12 cases of cutaneous melanoma (CM) confirmed by routine histopathology and immunohistochemistry in Shanghai Changzheng Hospital, Navy Military Medical University, were collected as CM group, while 17 cases of non-neoplastic skin diseases were collected as control group. The expression situation of microRNAs in serum and hair of two groups were detected by qRT-PCR. Candidate microRNAs with consistent results were identified as significant common differential expression biological indicators. The differentially expressed microRNAs (> 2.5 times) were screened by the multiple of differences between groups. Results There were 2 up-regulated and 5 down-regulated microRNAs in serum among 7 microRNAs of patients in CM group. The up-regulated microRNAs included miR-4487 and miR-4706, the down-regulated microRNAs included miR-16, miR-211, miR-4731, miR-509-3p and miR-514a. There were 3 up-regulated and 4 down-regulated microRNAs in hairs, the up-regulated microRNAs included miR-211, miR-4487 and miR-4731; the down-regulated microRNAs included miR-16, miR-4706, miR-509-3p and miR-514a. The co-up-regulated microRNAs in serum and hairs of the CM group were microRNAs-4487, but there was no statistically significant difference between the two groups (P > 0.05). Compared with the control group, the expressions of has-microRNA-16 and has-microRNA-509-3p were significantly down-regulated, the differences were statistically significant (P < 0.05), and with high consistency. Compared with control group, the expression of miRNA-541a in serum and hairs of CM group was down-regulated, but there was no statistically significant difference (P > 0.05). MiRNAs with more than 2.5 times differential expression in serum and hairs were miR-16 and miR-514a. In hair alone, miR-4706 was with differential expression of more than 2.5 times. The miR-4731 was more than 4 times differentially expressed in serum samples alone. MiRNAs with more than 10 times differential expression in serum were miR-211 and miR-509-3p. Conclusion Compared with non-cancer patients, there are many differentially expressed microRNAs in serum and hairs. There are highly significant differentially expressed microRNAs 211 and 509-3p in serum of CM patients, which can be used as biological markers of the tumor. Differential expression of microRNAs 4706 in hair samples may be the biology of early noninvasive detection of melanoma. Indicators. Detection of microRNAs is an available biological indicator for CM, and may become a means of target gene therapy in the future.

Key words： Cutaneous melanoma MicroRNA Signal transduction pathway Differential expression

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIN Qianli ZHANG Wenjun WANG Zhongzhi WANG Hui JIANG Hua

Cite this article:

LIN Qianli ZHANG Wenjun WANG Zhongzhi WANG Hui JIANG Hua. Differential expression of microRNAs in serum and hairs different position of cutaneous melanoma[J]. 中国医药导报, 2019, 16(26): 7-11,16.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I26/7

[1] Kudchadkar RR，Smalley KS，Glass LF，et al. Targeted therapy in melanoma [J]. Clin Dermatol，2013，31（2）：200-208.
[2] Meng F，Henson R，Wehbe-Janek H，et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer [J]. Gastroenterology，2007， 133（2）：647-658.
[3] Lorio MV，Ferracin M，Liu CG，et al. MicroRNA gene expression deregulation in human breast cancer [J]. Cancer Res，2005，65（16）：7065-7070.
[4] Svedman FC，Lohcharoenkal W，Bottai M，et al. Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma [J]. PLoS One，2018，13（11）：e0206942. doi：10.1371/journal. pone.0206942. eCollection 2018.
[5] Mohammadpour A，Derakhshan M，Darabi H，et al. Melanoma：Where we are and where we go [J]. J Cell Physiol，2019， 234（4）：3307-3320.
[6] Lee RC，Feinbaum RL，Ambros V. The C Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 [J]. Cell，1993，75（5）：843-854．
[7] Van Laar R，Lincoln M，Fereday S. Characterisation and validation of Mel38；A multi-tissue microRNA signature of cutaneous melanoma [J]. PLoS One，2019，14（2）：e0211504. doi：10.1371/journal.pone.0211504. eCollection 2019.
[8] Zhang L，Huang J，Yang N，et al. MicroRNAs exhibit high frequency genomic alterations in human cancer [J]．Proc Nail Acad Sci USA，2006，103（24）：9136-9141.
[9] Sabarimurugan S，Madurantakam Royam M，Das A，et al. Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients [J]. Mol Diagn Ther，2018，22（6）：653-669.
[10] Xu Y，Brenn T，Brown ER，et al. Differential expression of microRNAs during melanoma progression：miR-200C，miR-205 and miR-211 are downregulated in melanoma and act as tumor suppressors [J]. Br J Cancer，2012，106（3）：553-561. doi：10.1038/bjc.2011.568.
[11] Babapoor S，Horwich M，Wu R，et al. microRNA in situ hybridization form miR-211 detection as ancillary test in melanoma diagnosis [J]. Mod Pathol，2016，29（5）：461-475. doi：10.1038/modpathol.2016.44.
[12] Margue C，Philippidou D，Reinsbach SE，et al. New target genes of MITF - induced microRNA-211 contribute to melanoma cell invasion [J]. PLoS One，2013，8（9）：e73473. doi：10.1371/journal.pone.0073473. eCollection 2013.
[13] Díaz-Martínez M，Benito-Jardón L，Alonso L，et al. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma [J]. Cancer Res，2018，78（4）：1017-1030.
[14] Li Y，Li M，Shats I，et al. Glypican 6 is a putative biomarker for metastatic progression of cutaneous melanoma [J]. PLoS One，2019，14（6）：e0218067.doi：10.1371/journal.pone.0218067. eCollection 2019.
[15] Larsen AC. Conjunctival malignant melanoma in Denmark：epidemiology，treatment and prognosis with special emphasis on tumorigenesis and genetic profile [J]. Acta Ophthalmol，2016，94 Thesis 1：1-27. doi：10.1111/aos.13100.
[16] Stark MS，Tom LN，Boyle GM，et al. The "melanoma-enriched" microRNA miR-4731-5p acts as a tumor suppressor [J]. Oncotarget，2016，7（31）：49 677-49 687.
[17] Poell JB，van Haastert RJ，de Gunst T，et al. A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability [J]. PLoS One，2012，7（8）：e43569. doi：10.1371/journal.pone.0043569.
[18] Ke X，Zeng X，Wei X，et al. MiR-514a-3p inhibits cell proliferation and epithelial-mesenchymal transition by targeting EGFR in clear cell renal cell carcinoma [J]. Am J Transl Res，2017，9（12）：5332-5346.
[19] Davis ME，Zuckerman JE，Choi CHJ，et al． Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles [J]. Nature，2010，464：1067-1070.
[20] Swetter SM，Tsao H，Bichakjian CK，et al. Guidelines of care for the management of primary cutaneous melanoma [J]. J Am Acad Dermatol，2019，80（1）：208-250.